Vibe Rounds Cat Bank

Disclaimer: These are short, generalized summaries for learning purposes only — not a substitute for full appraisal of primary literature, current guidelines, or individualized clinical judgment. Evidence quality varies by topic; verify before applying to practice.

1 · Diagnosis

CAT 1 — Does ferritin distinguish IDA from anemia of chronic disease (ACD)?

Bottom line: Low ferritin (<30 ng/mL) is highly specific for IDA even with inflammation; normal/high ferritin does not rule out coexisting IDA. Raise the threshold (~70–100 ng/mL) when CRP/ESR are elevated.

CAT 2 — Does reticulocyte hemoglobin content (Ret-He) help detect iron-restricted erythropoiesis?

Bottom line: Ret-He responds faster than ferritin/MCV to iron status changes; useful for early detection, especially in dialysis and pediatric populations.

CAT 3 — Does soluble transferrin receptor (sTfR) add value over ferritin with inflammation present?

Bottom line: sTfR is less affected by inflammation and can help confirm IDA in ACD, but cost/availability limit routine use; ferritin remains first-line.

CAT 4 — Is peripheral smear review still necessary with automated indices available?

Bottom line: Yes when indices are discordant, cause is unexplained, or hemolysis/marrow failure is suspected — counters can miss schistocytes, blasts, target cells.

CAT 5 — What is the diagnostic yield of endoscopy in IDA without overt GI bleeding?

Bottom line: Bidirectional endoscopy finds a GI source in roughly one-third to half of adults with unexplained IDA; yield rises with age, especially in men and postmenopausal women.

CAT 6 — What Hb cutoff defines pathologic anemia in pregnancy?

Bottom line: WHO: Hb <11 g/dL (1st/3rd trimester) or <10.5 g/dL (2nd trimester). Values above this may still reflect suboptimal iron status due to physiologic hemodilution.

CAT 7 — Does bone marrow biopsy add value over peripheral testing in suspected aplastic anemia?

Bottom line: Required for diagnosis and severity grading — peripheral counts alone can't confirm hypocellularity or exclude infiltrative marrow disease.

CAT 8 — Is MCV alone reliable for classifying anemia etiology?

Bottom line: Useful first-pass filter but overlaps substantially between categories (e.g., early IDA can be normocytic) — should not be used in isolation.

CAT 9 — Does RDW help differentiate causes of microcytic anemia?

Bottom line: Elevated RDW favors IDA over thalassemia trait (usually normal RDW), though overlap exists — confirm with ferritin/hemoglobin electrophoresis.

CAT 10 — Is Coombs testing necessary in all suspected hemolytic anemia?

Bottom line: Yes — direct antiglobulin test (DAT) distinguishes immune from non-immune hemolysis and should be obtained early with LDH, haptoglobin, bilirubin.

2 · Therapy / Intervention

CAT 11 — Is oral iron as effective as IV iron in correcting IDA?

Bottom line: Comparable Hb normalization by 8–12 weeks in uncomplicated IDA with adequate absorption/tolerance. IV preferred if oral intolerant, absorption impaired (IBD, post-bariatric), or urgent correction needed.

CAT 12 — Does alternate-day oral iron dosing improve absorption vs daily dosing?

Bottom line: Improves fractional absorption and reduces GI side effects (hepcidin-mediated), with similar long-term efficacy in repleting stores.

CAT 13 — Do ESAs improve hard outcomes in CKD-associated anemia?

Bottom line: Raise Hb but don't improve mortality/CV outcomes; targeting Hb >13 g/dL increases stroke/thromboembolic risk. Conservative targets (~10–11.5 g/dL) recommended.

CAT 14 — Does IV iron reduce hospitalizations in heart failure with iron deficiency?

Bottom line: Ferric carboxymaltose improves functional status and reduces HF hospitalizations in iron-deficient HFrEF, regardless of anemia status; mortality benefit unproven.

CAT 15 — What is the optimal transfusion threshold in critically ill patients?

Bottom line: Restrictive strategy (transfuse <7 g/dL) is non-inferior to liberal strategies in most critically ill/stable cardiac patients — less exposure, no mortality increase.

CAT 16 — Does hydroxyurea reduce vaso-occlusive crises in sickle cell anemia?

Bottom line: Significantly reduces crisis frequency, acute chest syndrome, and transfusion need, and improves survival long-term. Remains underutilized in practice.

CAT 17 — Is oral B12 replacement as effective as IM injection?

Bottom line: High-dose oral B12 (1000–2000 mcg/day) is as effective as IM, including in pernicious anemia, given adherence. IM preferred if adherence/absorption is uncertain.

CAT 18 — Does preoperative iron optimization reduce transfusion needs?

Bottom line: Preoperative screening and correction (oral or IV) reduces perioperative transfusion rates and may shorten length of stay, especially in major ortho/cardiac surgery.

CAT 19 — If megaloblastic anemia's specific deficiency is unclear, are both B12 and folate needed?

Bottom line: Confirm/correct B12 before or alongside folate — giving folate alone in undiagnosed B12 deficiency can mask anemia while neurologic damage progresses.

CAT 20 — Does IV iron increase infection risk?

Bottom line: Mixed evidence; some studies suggest modestly increased risk (dialysis, ICU populations), but overall risk is low and doesn't generally outweigh benefit.

3 · Prognosis

CAT 21 — Is unexplained anemia in the elderly associated with increased mortality?

Bottom line: Yes — independently associated with increased mortality and frailty, even at mild severity, when no nutritional/renal/inflammatory cause is found.

CAT 22 — Does admission anemia predict outcomes in heart failure?

Bottom line: Associated with longer length of stay, higher readmission rates, and increased mortality, independent of ejection fraction.

CAT 23 — What is the prognostic significance of anemia at cancer diagnosis?

Bottom line: Associated with worse overall survival across most solid tumors, though partly reflects disease burden rather than pure causality.

CAT 24 — Does anemia in pregnancy predict adverse outcomes?

Bottom line: Severe anemia (and very high Hb) both associate with preterm birth and low birth weight — a U-shaped, not linear, relationship.

4 · Harm / Etiology

CAT 25 — Does long-term PPI use increase risk of iron/B12 deficiency anemia?

Bottom line: Yes — modestly increased risk of both, due to reduced acid-dependent absorption; risk rises with duration of therapy.

CAT 26 — Is NSAID use associated with occult GI blood loss and IDA?

Bottom line: Chronic NSAID/low-dose aspirin use increases occult GI blood loss — consider as a reversible contributor during IDA workup.

CAT 27 — Does IV iron carry significant hypersensitivity risk vs oral iron?

Bottom line: Modern formulations carry low but real risk (~0.1–0.2% serious reactions); oral iron has no such risk but more GI intolerance.

CAT 28 — Do ESAs increase thromboembolic risk in cancer-related anemia?

Bottom line: Yes — increased VTE risk, with some trials raising tumor-progression concerns. Use generally restricted to chemo-induced anemia with conservative Hb targets.

5 · Screening

CAT 29 — Should asymptomatic postmenopausal women be screened for IDA?

Bottom line: Routine screening not broadly recommended, but incidental IDA in this group warrants GI evaluation given elevated risk of occult malignancy.

CAT 30 — Is universal anemia screening in pregnancy better than risk-based screening?

Bottom line: Universal screening (≥1x/trimester) is standard given high prevalence and low cost/harm — favored over risk-based approaches, which miss asymptomatic cases.

How to Use This CAT Bank

Each entry is a starting point, not a final answer — trace back to primary literature or current guidelines before applying to a specific patient.
Review interval: re-appraise every 12–24 months, or sooner if practice-changing evidence emerges.
Version control: date every edit; track what changed and why rather than silently overwriting conclusions.
Use consistent PICO framing for any new CATs added, to keep the bank searchable and comparable.